<?xml version="1.0" encoding="UTF-8"?>
<p id="p0085">Remdesivir, an investigational monophosphoramidate prodrug of an adenosine analog, was developed between 2014 and 2016 in response to Ebola (
 <xref rid="bib57" ref-type="bibr">Tchesnokov et al., 2019</xref>). Similar to its promising effect on SARS-CoV-1 and MERS-CoV, remdesivir has displayed potent 
 <italic>in vitro</italic> activity against SARS-CoV-2 by acting as an RNA chain terminator by binding to the RNA-dependent RNA polymerase (RdRp) (
 <xref rid="bib60" ref-type="bibr">Wang et al., 2020a</xref>). Although, two recent clinical trials have showed that remdesivir was not associated with dramatic clinical improvement, many clinical trials are underway (
 <xref rid="bib2" ref-type="bibr">Beigel et al., 2020</xref>; 
 <xref rid="bib62" ref-type="bibr">Wang et al., 2020c</xref>).
</p>
